EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Meta Biomed Co. Ltd (059210) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Meta Biomed Co. Ltd KRW 6,997, price KRW 3,630, upside +92.8%, quality 34 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7059210005

MB Thin data Sep 24, 2026

Meta Biomed Co. Ltd

059210 · KQ

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value 6,997 KRW · Strongly undervalued (+93%)
!Quality 34/100
!Expensive Growth (revenue 5y +16.9 %/yr)
✓Solidly profitable · 10.9% net margin (TTM)
!Low debt · negative free cash flow
·0.62% dividend yield
✓Ranks above peers (6/8)
!Narrow moat 42/100
!Insider activity 30/100
!Evidence only low, so the estimate is less certain
!Weak on dividend: 12 out of 100
Watch Meta Biomed Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

6,383 KRW 1,964 KRW Fair Value 6,997 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 1,964 KRW – 6,383 KRW · fair‑value band 4,898 KRW – 9,096 KRW · the 3,630 KRW price screens below the 6,997 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.

Follow Meta Biomed Co. in your weekly email

Every Wednesday you see whether Meta Biomed Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials.

Show more

Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone products consisting of bone graft substitutes and cement; and cosmetic medical products, as well as ultrasonic imaging diagnosis devices. The company was formerly known as Metadental Co., Ltd. and changed its name to Meta Biomed Co., Ltd. in 2001. Meta Biomed Co., Ltd. was founded in 1990 and is headquartered in Cheongju, South Korea.

Stock analysis

Meta Biomed Co. Ltd (059210) currently trades at 3,630 KRW, while our model-based Fair Value estimate is 6,997 KRW, implying the stock looks roughly 48.1% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 10,290 KRW per share, and 13 of the 14 models we run sit above the 3,630 KRW price.

Bear case: the Asset-Based group reads lowest at 3,545 KRW, and 1 of the 14 models stay below the price. Evidence for this calculation is low.

Scenario range: 4,898 KRW (bear) to 9,096 KRW (bull), the price of 3,630 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Meta Biomed Co. Ltd reported revenue of 103B KRW in FY2025 versus 58.8B KRW in FY2021, a compound +15.0%/yr. Reported net income was 11.0B KRW in FY2025, compounding +3.6%/yr from FY2021.

Key figures

Market cap 97.3B KRW (≈ $71.5M) · P/S ratio 1.56 · Dividend yield 0.6% · Net margin 10.7% · Return on equity 2,568% · Return on assets (EBIT) 7.4% · Operating margin 9.0% · Revenue (TTM) 66.9B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 93%, 059210 screens cheaper than that median.

Fair Value models

Bear 4,898 KRW Fair Value 6,997 KRW Bull 9,096 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income 4,049 KRW 4,228 KRW 4,390 KRW 76
EPV 6,597 KRW 7,300 KRW 7,871 KRW 74
ROIC Compounder 6,914 KRW 8,237 KRW 9,775 KRW 72
All 14 models by family
Earnings-Based
Graham-Dodd 3,181 KRW 12,870 KRW 17,510 KRW 64
Lynch FV 3,215 KRW 4,593 KRW 5,971 KRW 61
PEG = 1.0 3,215 KRW 4,593 KRW 5,971 KRW 57
EPV 6,597 KRW 7,300 KRW 7,871 KRW 74
Multiples
P/E Multiple 7,718 KRW 10,290 KRW 12,863 KRW 63
P/S Multiple 5,964 KRW 7,952 KRW 9,939 KRW 58
P/B Multiple 5,964 KRW 7,952 KRW 9,939 KRW 55
EV/EBIT 12,363 KRW 16,239 KRW 20,116 KRW 66
EV/EBITDA 12,768 KRW 16,780 KRW 20,792 KRW 67
EV/Revenue 9,033 KRW 12,591 KRW 16,148 KRW 54
Asset-Based
NCAV (Graham) 2,646 KRW 3,545 KRW 5,292 KRW 54
Economic Profit
Residual Income 4,049 KRW 4,228 KRW 4,390 KRW 76
ROIC Compounder 6,914 KRW 8,237 KRW 9,775 KRW 72
Growth Earnings
Growth-Adj P/E 5,762 KRW 8,232 KRW 10,701 KRW 67

Open the full fair value analysis →

Notify me when 059210 reaches fair value

Put 059210 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 34/100

Of which business quality 41 · Market factors (momentum, volatility) 25

Profitability 45
Margins and returns on capital today
Quality Growth 44
Are margins and returns improving?
Cashflow 43
Earnings quality: real cash, not paper profit
Fin. Strength 68
Balance sheet, leverage, solvency risk
Investment 8
Disciplined investing over empire-building
Low Volatility 48
Calm price path (market factor)
Momentum 22
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 13
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.0%
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.9%
Dividend (yield on the price)0.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8% vs 30%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−6% → 21%
Start year 2020 (pandemic)

Watch 059210, get fair value alerts →

Compare Meta Biomed Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)Health Care · 2621 stocks

Beats the sector median on 6/8 measures
Overall it ranks above its sector peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside +93% · Top 25%
Profitability
Return on assets 3% · Above median
Net margin (TTM) 11% · Above median
Operating margin (TTM) 9% · Above median
Growth and dividend
Revenue growth 40% · Top 25%
Dividend yield (TTM) 0.6% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 6
FUTURE (revenue growth)100 · sector 21
PAST (return on equity)0 · sector 13
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)12 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
InBody Co 041830 53,200 KRW 58,520 KRW +10%
Value Added Technology Co 043150 17,460 KRW 48,636 KRW +179%
Mediana Co 041920 8,910 KRW 5,424 KRW −39%
Sewoon Medical Co 100700 2,290 KRW 5,541 KRW +142%
MEKICS CO., Ltd 058110 1,497 KRW 1,581 KRW +6%
INM INM 0.1095 PLN 0.0400 PLN −63%
NST NST 0.5000 PLN 0.1200 PLN −76%
Eli Lilly and Company LLY $1,182 $792.04 −33%
Johnson & Johnson, JNJ $270.68 $168.85 −38%
AbbVie Inc ABBV $265.12 $259.62 −2%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Meta Biomed Co. Ltd · Fair Value
6,997 KRW +48%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Meta Biomed Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/059210

Frequently asked questions

Is Meta Biomed Co. Ltd (059210) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 6,997 KRW versus a price of 3,630 KRW, about +93% upside (undervalued).
What is the fair value of 059210?
Our model-based fair value for Meta Biomed Co. Ltd is 6,997 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,630 KRW.
What is the quality score of 059210?
Meta Biomed Co. Ltd has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Meta Biomed Co. Ltd (059210)?
Our model-based price target is the fair value of 6,997 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 4,898 KRW, optimistic scenario 9,096 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Meta Biomed Co. Ltd stock forecast for 2026?
Our models put fair value at 6,997 KRW, about +93% upside versus a price of 3,630 KRW (undervalued). Cautious scenario 4,898 KRW, optimistic scenario 9,096 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Meta Biomed Co. Ltd (059210)?
Meta Biomed Co. Ltd reported trailing-twelve-month revenue of about 66.9B KRW (latest available figure, as of Sep 24, 2026).
Does Meta Biomed Co. Ltd pay a dividend?
Meta Biomed Co. Ltd currently shows a dividend yield of about 0.62% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Meta Biomed Co. Ltd (059210)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Meta Biomed Co. Ltd it is 6,997 KRW per share (as of Sep 24, 2026), against a price of 3,630 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Meta Biomed Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 059210 trades below its calculated fair value: price 3,630 KRW, fair value 6,997 KRW, a gap of about +93% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 059210?
No. The price is what the market pays today (3,630 KRW); the fair value is what the company's own numbers justify (6,997 KRW). For Meta Biomed Co. Ltd the two are 3,367 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Meta Biomed Co. Ltd worth?
The market values Meta Biomed Co. Ltd at about 97.3B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,630 KRW; our models calculate a fair value of 6,997 KRW per share.
What do the bullish and bearish scenarios say about 059210?
Our models span a range for Meta Biomed Co. Ltd: cautious scenario 4,898 KRW, base 6,997 KRW, optimistic 9,096 KRW per share (as of Sep 24, 2026, price 3,630 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Meta Biomed Co. Ltd (059210)?
Balance-sheet figures for Meta Biomed Co. Ltd (as of Sep 24, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 059210 from its 52-week high?
Meta Biomed Co. Ltd trades at 3,630 KRW, about 42% below its 52-week high of 6,256 KRW and 9% above the low of 3,335 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 6,997 KRW is for.
Which stocks are comparable to Meta Biomed Co. Ltd?
From the same area (Healthcare) we also value InBody Co, Value Added Technology Co, Mediana Co, Sewoon Medical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Meta Biomed Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 3,630 KRW, calculated fair value 6,997 KRW (+93%), Quality Score 34/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 059210 calculated?
We run Meta Biomed Co. Ltd through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6,997 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Meta Biomed Co. Ltd currently trades 93 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Meta Biomed Co. Ltd (059210)?
The closing price on Sep 23, 2026 was 3,630 KRW. Our model-based fair value is 6,997 KRW, about +93% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Meta Biomed Co. Ltd right now?
The large discount to fair value meets weak quality (34/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (4,898 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (4,898 KRW to 9,096 KRW) leaves room in how you read the outcome.

Key figures of Meta Biomed Co. Ltd

How large is the market capitalisation of Meta Biomed Co. Ltd (059210)?
The market capitalisation of Meta Biomed Co. Ltd is 97.3B KRW (≈ $71.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Meta Biomed Co. Ltd (059210)?
The price-to-sales ratio of Meta Biomed Co. Ltd is 1.56 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Meta Biomed Co. Ltd (059210)?
The dividend yield of Meta Biomed Co. Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Meta Biomed Co. Ltd (059210)?
The net margin of Meta Biomed Co. Ltd is 10.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Meta Biomed Co. Ltd (059210)?
The return on equity (ROE) of Meta Biomed Co. Ltd is 2,568% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Meta Biomed Co. Ltd (059210)?
On an EBIT basis the return on assets of Meta Biomed Co. Ltd is 7.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Meta Biomed Co. Ltd (059210)?
The operating margin of Meta Biomed Co. Ltd is 9.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Meta Biomed Co. Ltd (059210)?
Revenue at Meta Biomed Co. Ltd is growing +40.4% versus a year earlier (3y avg +14.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Meta Biomed Co. Ltd (059210)?
Earnings per share at Meta Biomed Co. Ltd are growing +45.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Meta Biomed Co. Ltd (059210) generate?
The free cash flow of Meta Biomed Co. Ltd is −628M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Meta Biomed Co. Ltd (059210) carry?
The net debt of Meta Biomed Co. Ltd is 24.1B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Meta Biomed Co. Ltd in the live analysis

One click puts Meta Biomed Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.